GPR75-ASB3: A Potential Drug Target and Biomarker (G100302652)

Target Name: GPR75-ASB3

NCBI ID: G100302652

GPR75-ASB3

GPR75-ASB3: A Potential Drug Target and Biomarker

G-protein-coupled receptors (GPCRs) are a family of transmembrane proteins that play a crucial role in cellular signaling. GPCRs are involved in various physiological processes, including sensory perception, neurotransmission, and hormone signaling. GPR75, also known as GPR75-ASB3, is a GPCR that has been identified as a potential drug target and biomarker. In this article, we will discuss the biology of GPR75, its potential as a drug target, and its potential as a biomarker for various diseases.

GPR75 is a 75-kDa protein that is expressed in various tissues, including the brain, pancreas, and peripheral tissues. GPR75 is a GPCR that is involved in the regulation of insulin secretion from pancreatic beta cells. Insulin is a critical hormone that regulates various physiological processes, including energy metabolism, growth, and inflammation. Malfunctioning insulin secretion has been linked to various diseases, including type 1 diabetes, obesity, and neurodegenerative disorders.

GPR75 has been shown to play a role in the regulation of insulin secretion by the pancreatic beta cells. GPR75 has been shown to interact with the transcription factor, Pdx1. Pdx1 is a known regulator of insulin secretion and has been shown to play a role in the development of insulin resistance. By interacting with Pdx1, GPR75 has been shown to regulate the expression of genes involved in insulin secretion.

In addition to its role in insulin secretion, GPR75 has also been shown to play a role in the regulation of inflammation. GPR75 has been shown to interact with the transcription factor, NF-kappa-B. NF-kappa-B is a known regulator of inflammation and has been shown to play a role in the development of various diseases, including cancer. By interacting with NF-kappa-B, GPR75 has been shown to regulate the expression of genes involved in inflammation.

GPR75 has also been shown to play a role in the regulation of pain perception. GPR75 has been shown to interact with the transcription factor, Trkm5. Trkm5 is a known regulator of pain perception and has been shown to play a role in the development of chronic pain. By interacting with Trkm5, GPR75 has been shown to regulate the expression of genes involved in pain perception.

GPR75 has also been shown to play a role in the regulation of body temperature. GPR75 has been shown to interact with the transcription factor, coregulator, heat shock factor 1 (HSF1). HSF1 is a known regulator of body temperature and has been shown to play a role in the regulation of various physiological processes, including temperature regulation.

In conclusion, GPR75 is a GPCR that has been shown to play a role in the regulation of insulin secretion, inflammation, pain perception, and body temperature. Its potential as a drug target and biomarker makes it an attractive target for future research. Further studies are needed to fully understand the biology of GPR75 and its potential as a drug and biomarker.

Protein Name: GPR75-ASB3 Readthrough

Functions: Probable substrate-recognition component of a SCF-like ECS (Elongin-Cullin-SOCS-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Recognizes TNFRSF1B

The "GPR75-ASB3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GPR75-ASB3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets